Cue Biopharma, Inc.

SecurityCUE / Cue Biopharma, Inc.
InstitutionNorthern Trust Corp
Latest Disclosed Ownership94,607 shares
Latest Disclosed Value $ 21,750
Northern Trust Corp reports 6.29% decrease in ownership of CUE / Cue Biopharma, Inc.

On May 14, 2026 - Northern Trust Corp filed a 13F-HR form disclosing ownership of 94,607 shares of Cue Biopharma, Inc. (US:CUE) valued at $21,750 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 100,958 shares of Cue Biopharma, Inc.. This represents a change in shares of -6.29% during the quarter. The current value of the position is $2,545,874 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-14 2026-03-31 13F CUE BIOPHARMA COM 22978P106 94,607 -6,351 -6.29 22 -30.00 0.0000
2026-02-17 2025-12-31 13F CUE BIOPHARMA COM 22978P106 100,958 0 0.00 31 -58.33 0.0000
2025-11-14 2025-09-30 13F CUE BIOPHARMA COM 22978P106 100,958 -31,615 -23.85 73 -20.00 0.0000
2025-08-13 2025-06-30 13F CUE BIOPHARMA COM 22978P106 132,573 -64,056 -32.58 90 -49.72 0.0000
2025-05-13 2025-03-31 13F CUE BIOPHARMA COM 22978P106 196,629 -11,577 -5.56 179 -20.80 0.0000
2025-02-14 2024-12-31 13F CUE BIOPHARMA COM 22978P106 208,206 69,892 50.53 227 117.31 0.0000
2024-11-13 2024-09-30 13F CUE BIOPHARMA COM 22978P106 138,314 -212,105 -60.53 105 -76.04 0.0000
2024-08-14 2024-06-30 13F CUE BIOPHARMA COM 22978P106 350,419 -14,763 -4.04 435 -37.10 0.0001
2024-05-14 2024-03-31 13F CUE BIOPHARMA COM 22978P106 365,182 -16,185 -4.24 690 -31.41 0.0001
2024-02-13 2023-12-31 13F CUE BIOPHARMA COM 22978P106 381,367 52,682 16.03 1,007 33.25 0.0002
2023-11-13 2023-09-30 13F CUE BIOPHARMA COM 22978P106 328,685 -2,750 -0.83 756 -37.55 0.0001
2023-08-11 2023-06-30 13F CUE BIOPHARMA COM 22978P106 331,435 253,135 323.29 1,210 333.33 0.0002
2023-05-15 2023-03-31 13F CUE BIOPHARMA COM 22978P106 78,300 15,711 25.10 280 56.74 0.0001
2023-02-13 2022-12-31 13F CUE BIOPHARMA COM 22978P106 62,589 0 0.00 178 28.06 0.0000
2022-11-14 2022-09-30 13F CUE BIOPHARMA COM 22978P106 62,589 2,115 3.50 139 -7.33 0.0000
2022-08-12 2022-06-30 13F CUE BIOPHARMA COM 22978P106 60,474 -243,872 -80.13 150 -89.91 0.0000
2022-05-13 2022-03-31 13F CUE BIOPHARMA COM 22978P106 304,346 -12,121 -3.83 1,486 -58.48 0.0003
2022-02-08 2021-12-31 13F CUE BIOPHARMA COM 22978P106 316,467 6,697 2.16 3,579 -20.70 0.0006
2021-11-15 2021-09-30 13F CUE BIOPHARMA COM 22978P106 309,770 -9,545 -2.99 4,513 21.28 0.0008
2021-08-13 2021-06-30 13F CUE BIOPHARMA COM 22978P106 319,315 -11,379 -3.44 3,721 -7.78 0.0007
2021-05-12 2021-03-31 13F CUE BIOPHARMA COM 22978P106 330,694 -13,051 -3.80 4,035 -6.16 0.0008
2021-02-11 2020-12-31 13F CUE BIOPHARMA COM 22978P106 343,745 -3,787 -1.09 4,300 -17.78 0.0008
2020-11-16 2020-09-30 13F CUE BIOPHARMA COM 22978P106 347,532 -3,686 -1.05 5,230 -39.24 0.0011
2020-08-14 2020-06-30 13F CUE BIOPHARMA COM 22978P106 351,218 114,744 48.52 8,608 156.57 0.0020
2020-05-14 2020-03-31 13F CUE BIOPHARMA COM 22978P106 236,474 16,401 7.45 3,355 -3.95 0.0010
2020-02-14 2019-12-31 13F CUE BIOPHARMA COM 22978P106 220,073 -3,579 -1.60 3,493 85.21 0.0008
2019-11-13 2019-09-30 13F CUE BIOPHARMA COM 22978P106 223,652 19,097 9.34 1,886 2.56 0.0005
2019-08-13 2019-06-30 13F CUE BIOPHARMA COM 22978P106 204,555 3,970 1.98 1,839 18.57 0.0004
2019-05-13 2019-03-31 13F CUE BIOPHARMA COM 22978P106 200,585 11,013 5.81 1,551 74.07 0.0004
2019-02-12 2018-12-31 13F CUE BIOPHARMA COM 22978P106 189,572 -1,401 -0.73 891 -48.44 0.0002
2018-11-14 2018-09-30 13F CUE BIOPHARMA COM 22978P106 190,973 10,487 5.81 1,728 -19.29 0.0004
2018-09-18 2018-06-30 13F/A-1 CUE BIOPHARMA COM 22978P106 180,486 105,333 140.16 2,141 102.75 0.0005
2018-08-14 2018-06-30 13F CUE BIOPHARMA COM 22978P106 180,486 105,333 2,141
2018-05-09 2018-03-31 13F CUE BIOPHARMA COM 22978P106 75,153 75,153 1,056 0.0003
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.